40641-90-5

Usage

Uses

Used in Pharmaceutical Industry:
Benzeneacetic acid, 4-cyclopropylis used as a key intermediate in the synthesis of various pharmaceuticals and drug candidates. Its unique structure allows for the development of novel compounds with improved pharmacological properties, such as enhanced potency, selectivity, and reduced side effects.
Used in Organic Synthesis:
In the field of organic synthesis, Benzeneacetic acid, 4-cyclopropylserves as a valuable building block for the preparation of a wide range of organic compounds. Its reactivity and functional group compatibility make it suitable for various synthetic transformations, enabling the creation of complex molecules with diverse applications.
Used in Antibacterial Applications:
Benzeneacetic acid, 4-cyclopropylhas been studied for its potential antibacterial properties. Its ability to inhibit the growth of certain bacteria makes it a promising candidate for the development of new antimicrobial agents, particularly in the context of increasing antibiotic resistance.
Used in Antifungal Applications:
Similarly, Benzeneacetic acid, 4-cyclopropylhas demonstrated antifungal activity, making it a potential candidate for the development of new antifungal agents. Its ability to target and inhibit fungal pathogens could contribute to the treatment of various fungal infections and diseases.

Upstream product

• 40641-91-6 4-[(4-cyclopropyl-phenyl)-thioacetyl]-morpholine 
• 40641-92-7 ethyl (4-cyclopropylphenyl)acetate 
• 1097870-73-9 methyl 2-(4-cyclopropylphenyl)acetate 
• 14062-25-0 Ethyl 4-bromophenylacetate 
• 63349-52-0 methyl 4-iodophenylacetate 
• 893738-65-3 2-(4-cyclopropylphenyl)acetonitrile 
• 16532-79-9 4-Bromophenylacetonitrile 

Downstream Products

• 1097870-77-3 (R)-4-benzyl-3-(2-(4-cyclopropylphenyl)acetyl)oxazolidin-2-one 

Relevant academic research and scientific papers

USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS

A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compo

T-TYPE CALCIUM CHANNEL BLOCKER

To provide a novel T-type calcium channel blocker. A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, the stereoisomer, or the salt is used as a T-type calcium channel blocker. wherein A represents a phenyl which may have a substituent, a 4-membered to 6-membered heteroaryl ring composed of one to three identical or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom and carbon atoms as ring-constituting atoms, or a heterocondensed ring composed of the heteroaryl ring and either a benzene ring or a 6-membered heteroaryl ring composed of one to two nitrogen atoms and carbon atoms, wherein the heteroaryl ring or the heterocondensed ring may have a substituent and is bonded to a nitrogen atom of the adjacent cyclic amino by means of a carbon atom constituting these rings; B represents a phenyl which may have a substituent, a 5-membered or 6-membered heteroaryl ring composed of one to three identical or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom and carbon atoms as ring-constituting atoms, or a heterocondensed ring composed of the heteroaryl ring and either a benzene ring or a 6-membered heteroaryl ring composed of one to two nitrogen atoms and carbon atoms, wherein the heteroaryl ring or the heterocondensed ring may have a substituent and is bonded to the adjacent cyclopropyl ring by means of a carbon atom constituting these rings; R1 and R2, which may be identical or different, each represent a hydrogen atom, a halogen atom, or the like; R3 represents a hydrogen atom, a halogen atom, or the like; n and m, which may be identical or different, each represent 0 or 1; and p represents 1 or 2.

COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE

The invention provides a combination of a) a compound of Formula Ia: [insert Formula Ia], or a pharmaceutically acceptable salt thereof, and b) vemurafenib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hy

2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES

The present invention provides a compound of Formula (I) or a pharmaceutically salt thereof wherein R1, R2, Ra, L, Z, Z1 and Z2 are as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.

Pyridyl amides as potent inhibitors of T-type calcium channels

A novel series of amide T-type calcium channel antagonists were prepared and evaluated using in vitro and in vivo assays. Optimization of the screening hit 3 led to identification of the potent and selective T-type antagonist 37 that displayed in vivo eff

PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds of Formula (I), including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS

The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.